Company intelligence / Profile preview

MindRank

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

MindRank has advanced its oral small-molecule GLP‑1 receptor agonist MDR‑001 to Phase II for obesity and type 2 diabetes. Its dual WEE1/YES1 kinase inhibitor MRANK‑106 received FDA IND clearance in March 2025 for multiple solid tumors, with a Phase I trial set to begin in 2025. Preclinical data show strong efficacy and safety profiles for these candidates.

Therapeutic areas: EndocrinologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

11 assets

MDR-001

10 more assets in the full pipeline.

Request access →

Partnerships

BioMetas Co., Ltd. – strategic partnership for preclinical R&D services and platform integrationMultiple public biotech companies as co-development partners or clients on design-as-a-service projects

Beyond the preview

Go deeper on MindRank.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindRank.

Explore the full profile